FAQ/Help |
Calendar |
Search |
Today's Posts |
|
12-08-2013, 11:02 PM | #1 | |||
|
||||
Senior Member
|
This may be old news, but I just read it tonight. 23andMe has conceded to the FDA's request for them to NOT offer genetic testing to new consumers. In 23andMe's eyes, this is just a temporary hold on offering the kits, and they plan to continue to negotiate with theFDA to get clearance.
Consumers who purchased kits prior to November 22; 2013, will continue to have access to all reports and results as before the FDA intervention. A full refund will be offered by email. Just thought this was interesting.I wonder what set this change of FDA to occur - we probably don't want to know. Read full letter dated December 5, 2013 Peggy http://blog.23andme.com/news/23andme...FUMV7AodWTwAAA |
|||
Reply With Quote |
12-09-2013, 07:15 AM | #2 | ||
|
|||
Senior Member
|
[QUOTE 23andMe has conceded to the FDA's request for them to NOT offer genetic testing to new consumers. In 23andMe's eyes, this is just a temporary hold on offering the kits, and they plan to continue to negotiate with theFDA to get clearance. ...."
“The 500,000+ customers we have today have given us more than 250 million survey data points.” … with open access of Big Data to researchers; and personal access to your own personal DNA map… for $99 In a few short years, they have built up a specific, focused data base that puts most of BigPharma to shame. Without taxpayers money; without charity donations. Google co-founder and neuro patient Sergey Brin, and his wife, Anne Wojcicki, have the Google Empire to back them up. They have taken bio-research online, and personalized it on one side and universalized it on the other side. Parkinson organisations talk about getting a Parkinson patient “at the table”, so “our interests will be heard”. In this case, it was a Parkinson patient who designed the table, created it, paid for it, launched it out to the world without getting on their knees … half a million patients signed up, taking charge of their own health care – a PD e-mailing list of half a million people who sent in $99 each and would be willing to send more if new breakthroughs look possible… Well that’s the kind of thing you want the government to protect you from. It might slow down research if DNA analysis is ordered up by any Tom, **** or Harry. Clinics charge $4,000 for that – what’s this thing about $99? And what pills are being sold with it? Amgen GDNF; the deliberately induced world-wide sinemet shortage that went on for 3 years; with supplied of sinemet being shifted from one country to another in secrecy; 50% of clinical trial results kept hidden; American pharma selling Duodopa for 15 years in Europe but not in America; while getting injunctions in Europe to keep its files secret; while proclaiming itself “proud Parkinson partner”; Medtronic class 1 recall (“danger of death”) revealed three months later by the business press… 23 and me shut down after 500,000 individuals voluntarily signed up and paid for… a Parkinson creation – a revolution in medicine.. … and what will be the reaction? Just another brick in the wall. That dog-whistle sound you don’t hear is the silence of the lambs. Move along now. Nothing to see here. Don’t frighten the horses. |
||
Reply With Quote |
12-09-2013, 10:53 AM | #3 | ||
|
|||
Member
|
|
||
Reply With Quote |
"Thanks for this!" says: |
12-09-2013, 02:00 PM | #4 | ||
|
|||
Senior Member
|
|
||
Reply With Quote |
12-09-2013, 03:16 PM | #5 | ||
|
|||
Member
|
Hate to keep playing devil's advocate (that's usually ST's role), but I'll give it a shot once again. Keep in mind that I am all for genetic testing and have done so myself several times. It's the inconsistency in my results that has me keeping an open mind with regard to the ongoing battle between 23andMe and the FDA.
First, let's get things straight. 23andMe is NOT shut down. For the 500,000 people who were tested prior to November 22, nothing has changed at all. You will have complete access to all data and the 23andMe interpretations of that data. Second, for their new customers, they will still have access to their raw data and the ability to see their genotype for any of the million or so SNPs that 23andMe reports on. What they will not get to see is 23andMe's disease risk analysis and interpretation of those results. My point is, things are not so dire and desperate as some are reporting. There are any number of ways for customers to get interpretations on those results. Unfortunately, many of those analyses will differ from each other, and from the way 23andMe may have reported. But of course, that's the whole issue in the first place. Lack of consistency across the industry. Didn't anyone find it strange that in both the letter that 23andMe sent to its customers as well as the more detailed blog on their site, they never actually addressed this issue. What they said was: "We also want to make clear that we stand behind the data we have generated for customers. Our lab partner adheres to strict quality standards that are part of the Clinical Laboratory Improvement Amendments of 1988 — known as CLIA. These are the same standards used in the majority of other health and disease-related tests. We decided several years ago to comply with CLIA guidelines to be consistent with other types of laboratory testing and to assure customers about the quality of data" However, these guidelines refer to their testing techniques and the genotype results which they report. No one is questioning the accuracy of these results. It's the risk analyses and interpretations that are of concern. How come 23andMe doesn't come out and state that their risk analyses and result interpretations are valid. That's all I'm asking for. Yet, they don't even comment on that important issue. As they, and others on this board have stated, they have 250 million bits of information from 500,000 people collected over many years. That would seem to be more than enough information to validate some results and report them to us. We all keep asking for more open information, why does 23andMe get to slide from this responsibility. Why can't a customer, like me, be given a reasonable answer as to why one genetic testing company tells me I have a high risk for a disease and a competitor, using the same raw data, informs me I have lower than average risk. Just some questions I would like answered and why I think the issue is more gray rather than black or white. Thanks, Gary |
||
Reply With Quote |
"Thanks for this!" says: | Bob Dawson (12-09-2013), lab rat (12-10-2013), Nan Cyclist (12-09-2013), soccertese (12-09-2013), Stand Tall (12-11-2013), Thelma (12-09-2013) |
12-09-2013, 04:10 PM | #6 | ||
|
|||
Magnate
|
are you ready to take on global warming?
gotta think lawyers are directing all their p.r.'s. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
23andme now $99! | Peripheral Neuropathy | |||
23andme | The Stumble Inn | |||
23andMe | Parkinson's Disease | |||
23AndMe Surveys | Parkinson's Disease | |||
23andme has it right re shipping | Parkinson's Disease |